

2025 American Society of
Hematology Annual Meeting

Servier Pharmaceuticals Abstracts

ABSTRACTS

2025 American Society of Hematology Annual Meeting

SERVIER 

Title

SUNDAY, DECEMBER 7 | 6:00–8:00 PM

ALIDHE: An Ongoing Open-Label Phase 3b Study Investigating Ivosidenib With Azacitidine in Clinical Practice in Adult Patients With Newly Diagnosed Mutant Isocitrate Dehydrogenase 1 Acute Myeloid Leukemia (mIDH1 AML) Ineligible for Intensive Induction Chemotherapy

SUNDAY, DECEMBER 7 | 6:00–8:00 PM

CYP3A4 Inhibitors and Myelosuppression in Patients with Newly Diagnosed Mutant Isocitrate Dehydrogenase 1 Acute Myeloid Leukemia in The Phase 3 AGILE Study

SUNDAY, DECEMBER 7 | 6:00–8:00 PM

Real-World Overall Survival in Patients with Acute Myeloid Leukemia Treated with Ivosidenib plus Azacitidine in the USA: Trinetx-Based Analysis

MONDAY, DECEMBER 8 | 4:45–5:00 PM

Updated Response and Safety Analyses from a Phase 1 Study of Ivosidenib Combined with Intensive Chemotherapy in Patients with Newly Diagnosed Acute Myeloid Leukemia with Isocitrate Dehydrogenase 1 Mutation

MONDAY, DECEMBER 8 | 6:00–8:00 PM

Phase 1/2, Multi-Center, Open-Label Clinical Study to Evaluate the Safety, Pharmacokinetics, and Efficacy of Zefamenib in Patients with Relapsed/Refractory Acute Leukemia

ONLINE-ONLY ABSTRACT

PyramIDH: A Phase 3 Study of Ivosidenib Monotherapy or Azacitidine Monotherapy in Patients With Mutant Isocitrate Dehydrogenase 1 (mIDH1) Myelodysplastic Syndromes Who Have Not Received Prior Hypomethylating Agent Therapy

ONLINE-ONLY ABSTRACT

Ivosidenib With or Without Hypomethylating Agent in IDH1-Mutated AML: Real-World Evidence to Inform Frontline Therapy

Presentation

POSTER PRESENTATION

P. Vyas

University of Oxford, United Kingdom

POSTER PRESENTATION

A. C. Schuh, BSc, MD, FRCPC

Princess Margaret Cancer Centre, Canada

POSTER PRESENTATION

J.F. Zeidner, MD

UNC Health

ORAL PRESENTATION

E.M. Stein, MD

Memorial Sloan Kettering Cancer Center

POSTER PRESENTATION

D. Wu, MD, PhD

Soochow University, Suzhou, China

ONLINE-ONLY ABSTRACT

M. Sebert, MD, PhD

Hôpital Saint-Louis, Paris, France

ONLINE-ONLY ABSTRACT

T. Bhagnani

Servier Pharmaceuticals

Investigator Sponsored Abstracts

SATURDAY, DECEMBER 6 | 5:30–7:30 PM

A Phase II Study of IDH1 Inhibition With Ivosidenib as Maintenance Therapy After Ivosidenib, Azacitidine, and Venetoclax for Acute Myeloid Leukemia: Trial in Progress

SATURDAY, DECEMBER 6 | 5:30–7:30 PM

Real Life Study of Ivosidenib in either Monotherapy or Combined With Azacitidine for First Line Mutant IDH1 AML: A Study From the French AML Intergroup ALFA/FILO

SUNDAY, DECEMBER 7 | 4:45–5:00 PM

Outcome of Children and Adolescents With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia: Results of DFCI ALL Consortium Protocol 16-001

SUNDAY, DECEMBER 7 | 5:30–5:45 PM

Ivosidenib Leads to Durable Responses in IDH1 Mutated Clonal Cytopenias of Undetermined Significance: A Phase II Decentralized Clinical Trial

SUNDAY, DECEMBER 7 | 6:00–8:00 PM

Ivosidenib in Refractory or Relapsed IDH1-Mutated Acute Myeloid Leukemia Patients in Real Life Settings: The IVOOBS Observational Study From the French AML Intergroup ALFA/FILO

MONDAY, DECEMBER 8 | 6:00–8:00 PM

Trial in Progress – A Phase Ib Trial of Ivosidenib Combined With Ruxolitinib in IDH1-Mutated Advanced Myeloproliferative Neoplasms

MONDAY, DECEMBER 8 | 6:00–8:00 PM

Phase 3 Study of Ivosidenib (IVO) and Azacitidine (AZA) With or Without Venetoclax in Adult Patients With Newly Diagnosed IDH1-Mutated AML or MDS/AML Ineligible for Intensive Chemotherapy (EVOLVE-1)

MONDAY, DECEMBER 8 | 6:00–8:00 PM

A Phase I Study of Venetoclax in Combination with Multiagent Cytotoxic Chemotherapy for Children and Adolescents with Relapsed or Refractory Acute Lymphoblastic Leukemia or Mixed Phenotype Acute Leukemia: Results of the Dose Determination Cohort

ONLINE-ONLY ABSTRACT

Ivosidenib Combined With Venetoclax and Azacitidine for the Treatment of Newly Diagnosed IDH1-Mutant Acute Myeloid Leukemia: A Prospective, Two Cohorts, Multicenter Study

ONLINE-ONLY ABSTRACT

Increased Yield of Recurrent Structural Variants in Ph-Like B-ALL Using a Streamlined Clinical Whole-Genome Sequencing Assay (Alliance)

ONLINE-ONLY ABSTRACT

Phase 1/2, Multi-Center, Open-Label Clinical Study to Evaluate the Safety, Pharmacokinetics, and Efficacy of Zefamenib Combined With Chemotherapy or Targeted Agents in Patients With Acute Myeloid Leukemia

POSTER PRESENTATION

K. Chin, MD

Memorial Sloan Kettering Cancer Center

POSTER PRESENTATION

P. Peterlin, MD

CHU de Nantes, France

ORAL PRESENTATION

M.A Burns, MD

Dana-Farber/Boston Children's Cancer and Blood Disorders Center

ORAL PRESENTATION

K. Bolton, MD, PhD

Washington University in St. Louis

POSTER PRESENTATION

M. Heiblig, MD

Centre Hospitalier Lyon Sud, France

POSTER PRESENTATION

A. Patel, MD

University of Chicago

POSTER PRESENTATION

H. Döhner, MD

Ulm University, Germany

POSTER PRESENTATION

M.A Burns, MD

Dana-Farber/Boston Children's Cancer and Blood Disorders Center

ONLINE-ONLY ABSTRACT

S. Chen

The First Affiliated Hospital of Soochow University, Suzhou, China

ONLINE-ONLY ABSTRACT

A. E. O. Hughes, MD, PhD

Washington University School of Medicine

ONLINE-ONLY ABSTRACT

H. Dai